Led by a surprise profit and renewed policy optimism, cannabis stocks experienced a powerful upswing on Thursday, sparking debate on whether the long-battered sector is turning a corner.
In a stunning single-day rally, Tilray Brands, Inc. (NASDAQ: TLRY) saw its shares surge 22.09% to close at $2.10 on Thursday, after touching a new 52-week high of $2.32. Trading volume exploded to nearly 298 million shares, roughly four times its three-month average, signaling a massive return of investor interest.
The catalyst was the cannabis producer’s better-than-expected quarterly earnings report released pre-market. For the quarter, Tilray posted net revenue of $209.5 million, a 5% year-over-year increase. Crucially, the company reported a net profit of $1.5 million, a significant turnaround from a net loss in the same period last year. While its gross margin saw a slight contraction, the company reaffirmed its full-year profit guidance and highlighted an improvement in operating cash flow, bolstering confidence in its diversified business strategy.
The rally was supercharged by a major regulatory tailwind emanating from Washington, D.C. The U.S. Drug Enforcement Administration (DEA) is currently considering a historic move to reclassify marijuana from a Schedule I substance—a category that includes drugs like heroin—to the less restrictive Schedule III, which acknowledges accepted medical uses.
This potential shift is critical for the industry’s economics. If enacted, it would relieve U.S. cannabis companies from the burdensome Section 280E of the U.S. tax code, which currently prohibits businesses dealing in Schedule I or II substances from deducting ordinary business expenses, severely hampering their profitability.
The optimism proved contagious across the sector. Canopy Growth Corporation (CGC) climbed 7.84% to $1.65, while SNDL Inc. (SNDL) rose 7.03% to $2.82. The surge in these speculative assets stood in sharp contrast to the broader market, where the S&P 500 and Nasdaq Composite edged down 0.28% and 0.08%, respectively.
The dramatic gains offer a glimmer of hope for a sector that has been mired in a prolonged downturn. Over the past five years, the AdvisorShares Pure US Cannabis ETF (MSOS) has plummeted approximately 77%, while the S&P 500 has nearly doubled. Despite a 27% gain year-to-date, Tilray’s stock remains down 46% over three years. Its current market capitalization of around $1.8 billion represents a staggering 90% decline from its peak of nearly $17 billion in early 2021.
Valuation metrics suggest the sector is still priced for distress. Tilray trades at a price-to-sales ratio of just 1.8 and a price-to-book ratio of 1.2, reflecting deep-seated market skepticism. Analysts note that this leaves substantial room for a valuation re-rating should federal laws in the U.S. be relaxed.
However, industry observers urge caution, pointing to a history of failed reform efforts that have led to previous “wolf” cries. The market’s enthusiasm may once again be getting ahead of the actual policy outcome. “For investors with a higher risk tolerance and a long-term horizon, current valuations may present a strategic entry point,” one analyst noted, adding that “the key unlock remains federal permissibility.”
A unique challenge for Tilray, as a Canadian company, is its current inability to directly participate in the U.S. cannabis market. The company has strategically positioned itself for a potential U.S. opening through investments in American beverage alcohol companies. Should federal prohibition ease, Tilray’s long-game strategy could rapidly accrue significant value.
For now, the question on every trader’s mind is whether this surge marks a definitive rebirth for cannabis stocks or merely another fleeting rally in a notoriously volatile industry.
